Eurofins Discovery Announces Collaboration with Escient Pharmaceuticals
SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a collaboration with Escient Pharmaceuticals, Inc.. Eurofins Discovery has successfully collaborated with clients in integrated drug discovery programs and has a strong record of accomplishment of preclinical candidate delivery. The integrated services are marketed under the brand name of DiscoveryOne™.
Escient recently launched in San Diego with $40 million in Series A financing and is leveraging Eurofins' expertise in assay development and GPCR drug discovery to identify novel therapeutics targeting Mas-Related G-Protein Receptors (Mrgpr). Under the terms of the ongoing collaboration, Eurofins will support in vitro preclinical discovery efforts for Escient's programs by providing expertise and services. "The preclinical discovery support required for Escient's novel drug targets plays well to Eurofins' expertise and capabilities and this collaboration will greatly expedite our discovery path," said Marcus F. Boehm Ph.D., Escient's Chief Scientific Officer.
"We are thrilled with the value that we can offer our clients," stated Christina Shasserre, Sr. VP of Eurofins Discovery. "We have been offering services for all phases of drug discovery and can now assemble this offering into an integrated service with program management staffed from experts in drug discovery, termed DiscoveryOne™. This will provide our clients with the critical expertise to support their delivery of a preclinical candidate."
About Eurofins Discovery
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP)
View original content to download multimedia:http://www.prnewswire.com/news-releases/eurofins-discovery-announces-collaboration-with-escient-pharmaceuticals-300944571.html
SOURCE Eurofins Discovery
Company Codes: EuronextParis:ERF, OTC-PINK:ERRFY